Zymofix
ActiveSummary
The annual accounts of Zymofix for financial year 2025 show a net loss of 51% of the equity at the start of that year. The 2025 annual accounts show equity of €1.6m and a net result of -€636,911. Equity has been growing by about 77% per year since 2023. Its solvency ranks better than 60% of 239 sector peers (NACE 72, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active since 25-07-2022 Normal situation
- Registered office
- 60 active companies are registered at this address Source: KBO register, as of 2 November 2026.
- Activity
- Research and development on biotechnology NACE 72101and 1 other
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 2025
- Establishment units
- 2.343.258.593 9032 Gent, since 25-07-2022
- 2.363.324.925 9850 Deinze, since 01-01-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 05-01-2026
Board and ownership
- Boris DORINDirector
- Redant, EmileDirector
- Auditor
- Finvision Bedrijfsrevisoren
- D.C. Energy23.44%2024 annual accounts of D.C. Energy
- Het Vroonhof2024 annual accounts of Het Vroonhof
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €150,474
- Turnover
- ≈ €380,000
- estimated
- Loss
- €636,911
- ▲ 23.6%
- Equity
- €1.6m
- ▲ 26.1%
- Total assets
- €2.4m
- ▲ 9.0%
- Employees on 31-12-2025
- 16
- ▲ 129%
Score breakdownraises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €636,911, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 2.79, cash €1.1mSector: Scientific research and development (NACE 72)Equity €1.6m (65.5% of total assets)Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small). It does better than 61% of them on solvency, 88% on liquidity, 11% on profitability and 74% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 3 accounts on average 5 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Resignations: CRESCENDO, Redemi and 2 othersPermanent representatives: VAN MELLAERT Herman, REDANT Emile and 2 others · Appointments: CRESCENDO, Redemi and 3 others
- · Gazette deed Company renamed from N-Fix to ZymofixAppointment: FINVISION BEDRIJFSREVISOREN (statutory auditor)
- · Gazette deed Appointment: CRESCENDO (director)Permanent representative: Herman Van Mellaert
Comparable companies
These companies have the same main activity as Zymofix: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €1.1m and €4.6m, founded between 2020 and 2023.
| Company | Total assets | Gross margin |
|---|---|---|
| Zymofix Gent | €2.4m | €0.2m |
| CM4Cure Liège | €4.6m | €0.6m |
| Xper Research Oudenaarde | €1.1m | €1.3m |
| Puxano Gent | €2.4m | €0.6m |
| Santero Therapeutics Charleroi | €4.2m | €1.0m |
| Fishway Leuven | €3.0m | €0.4m |
| ImmuneSpec Niel | €3.5m | €0.9m |
Key facts about Zymofix
- What is the company number of Zymofix?
- The company number of Zymofix is 0788.847.055. The VAT number is the same number with BE in front: BE 0788.847.055.
- Where is Zymofix based?
- The registered office is at Waterlelielaan 1, 9032 Gent.Company details
- What does Zymofix do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of Zymofix?
- The legal form of Zymofix is Public limited company (NV).
- When was Zymofix founded?
- Zymofix was founded on 25-07-2022.
- Is Zymofix still active?
- Yes, Zymofix is an active enterprise in the KBO register.
- How many employees does Zymofix have?
- Zymofix had an average of 12.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Zymofix fall under?
- In its 2025 annual accounts, Zymofix states joint committee 200 (Aanvullend Paritair Comité voor de bedienden).
- What is the turnover of Zymofix?
- The turnover in financial year 2025 is ≈ €380,000. This figure is estimated from the gross margin of €150,474 and 1,647 comparable companies of the same size. It probably lies between €230,000 and €720,000. It is a rough estimate.
- Is Zymofix profitable?
- In financial year 2025, Zymofix made a loss of €636,911.
- Where can I find the annual accounts of Zymofix?
- Zymofix filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Zymofix due?
- Zymofix must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.